Supplementing transglucosidase with a high-fiber diet for prevention of postprandial hyperglycemia in streptozotocin-induced diabetic dogs.
Indigestible oligosaccharides have been shown to normalize blood glucose and insulin concentration thereby promoting good health and preventing diseases, such as diabetes. Transglucosidase (TG, alpha-glucosidase, enzyme code (EC) 3.2.1.20) is an enzyme capable of converting starch to oligosaccharides, such as iso-malto-oligosaccharides from maltose, via the action of amylase. The aim of this study was to evaluate whether oral administration of TG with maltose or dextrin is capable of reducing post-prandial serum glucose concentration in experimentally streptozotocin (STZ)-induced diabetic dogs fed on a high-fiber diet. Five healthy and five STZ-induced diabetic dogs were employed in this study. TG supplementation with dextrin or maltose had no detrimental effect in healthy dogs. In fact, TG and dextrin exhibited a flatlined serum glucose pattern, while reducing mean post-prandial serum insulin and glucose concentration as compared to control diet alone. When TG supplementation was tested in STZ-induced diabetic dogs under the context of a high fiber diet, a 13.8% and 23.9% reduction in mean glucose concentration for TG with maltose and dextrin, respectively was observed. Moreover, TG with dextrin resulted in a 13% lower mean post-prandial glucose concentration than TG with maltose, suggesting that dextrin may be a more efficient substrate than maltose when used at the same concentration (1 g/kg). Our results indicate that TG supplementation with diet can lead to lower postprandial glucose levels versus diet alone. However, the efficacy of TG supplementation may depend on the type of diet it is supplemented with. As such, TG administration may be useful for preventing the progression of diabetes mellitus and in its management in dogs.
Sako
Toshinori
T
School of Veterinary Nursing & Technology, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo, 180-8602, Japan.
Mori
Akihiro
A
Lee
Peter
P
Goto
Hiroshi
H
Fukuta
Hiroko
H
Oda
Hitomi
H
Saeki
Kaori
K
Miki
Yohei
Y
Makino
Yuki
Y
Ishioka
Katsumi
K
Mizutani
Hisashi
H
Kojima
Yuzo
Y
Koikeda
Satoshi
S
Arai
Toshiro
T
D000818:Animals; D019540:Area Under Curve; D001786:Blood Glucose / Q000378:metabolism; D003912:Dextrins / Q000008:administration & dosage / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000178:diet therapy / Q000378:metabolism / Q000517:prevention & control*; D003922:Diabetes Mellitus, Type 1 / Q000178:diet therapy / Q000378:metabolism / Q000517:prevention & control / Q000662:veterinary*; D004043:Dietary Fiber / Q000008:administration & dosage* / Q000378:metabolism; D019587:Dietary Supplements; D004283:Dog Diseases / Q000178:diet therapy* / Q000378:metabolism / Q000517:prevention & control; D004285:Dogs; D005260:Female; D005959:Glucosidases / Q000008:administration & dosage* / Q000378:metabolism; D006943:Hyperglycemia / Q000378:metabolism / Q000517:prevention & control / Q000662:veterinary*; D007328:Insulin / Q000097:blood; D008297:Male; D008320:Maltose / Q000008:administration & dosage / Q000378:metabolism
D001786:Blood Glucose; D003912:Dextrins; D004043:Dietary Fiber; D007328:Insulin; D008320:Maltose; D005959:Glucosidases